Antibodies Targeted to the Brain with Image-Guided Focused Ultrasound Reduces Amyloid-β Plaque Load in the TgCRND8 Mouse Model of Alzheimer's Disease

Jessica F. Jordão, Carlos A. Ayala‐Grosso, Kelly A. Markham, Yuexi Huang, Rajiv Chopra, JoAnne McLaurin, Kullervo Hynynen, Isabelle Aubert

PLoS ONE · 2010 · 384 citations · 27 references

DOIFull text

Open access

Concepts

TL;DR

Alzheimer’s disease immunotherapy uses anti‑amyloid‑β antibodies that circulate in the bloodstream, but direct brain delivery has been shown to more effectively reduce plaque pathology, and transcranial focused ultrasound transiently opens the blood‑brain barrier to permit intravenously administered therapeutics to enter the brain. The study aimed to determine whether MRI‑guided focused ultrasound‑mediated delivery of anti‑Aβ antibodies to the brain can reduce amyloid‑β plaque load. In TgCRND8 mice, intravenous BAM‑10 and contrast agents were administered, followed by transcranial MRI‑guided focused ultrasound to open the BBB. Within minutes, BAM‑10 bound to amyloid‑β plaques in targeted cortical regions, and four days later plaque load was significantly reduced, demonstrating that MRI‑guided focused ultrasound delivery of anti‑Aβ antibodies rapidly lowers plaque pathology with a low antibody dose.

Abstract

Immunotherapy for Alzheimer's disease (AD) relies on antibodies directed against toxic amyloid-beta peptide (Aβ), which circulate in the bloodstream and remove Aβ from the brain [1], [2]. In mouse models of AD, the administration of anti-Aβ antibodies directly into the brain, in comparison to the bloodstream, was shown to be more efficient at reducing Aβ plaque pathology [3], [4]. Therefore, delivering anti-Aβ antibodies to the brain of AD patients may also improve treatment efficiency. Transcranial focused ultrasound (FUS) is known to transiently-enhance the permeability of the blood-brain barrier (BBB) [5], allowing intravenously administered therapeutics to enter the brain [6]–[8]. Our goal was to establish that anti-Aβ antibodies delivered to the brain using magnetic resonance imaging-guided FUS (MRIgFUS) [9] can reduce plaque pathology. To test this, TgCRND8 mice [10] received intravenous injections of MRI and FUS contrast agents, as well as anti-Aβ antibody, BAM-10. MRIgFUS was then applied transcranially. Within minutes, the MRI contrast agent entered the brain, and BAM-10 was later found bound to Aβ plaques in targeted cortical areas. Four days post-treatment, Aβ pathology was significantly reduced in TgCRND8 mice. In conclusion, this is the first report to demonstrate that MRIgFUS delivery of anti-Aβ antibodies provides the combined advantages of using a low dose of antibody and rapidly reducing plaque pathology.

References

27